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Staphylococcus aureus bacteremia (SAB) is common
and increasing worldwide. A retrospective review was
undertaken to quantify the number of cases, their place of
acquisition, and the proportions caused by methicillin-
resistant S. aureus (MRSA) in 17 hospitals in Australia. Of
3,192 episodes, 1,571 (49%) were community onset.
MRSA caused 40% of hospital-onset episodes and 12% of
community-onset episodes. The median rate of SAB was
1.48/1,000 admissions (range 0.61–3.24; median rate for
hospital-onset SAB was 0.7/1,000 and for community onset
0.8/1,000 admissions). Using these rates, we estimate that
≈6,900 episodes of SAB occur annually in Australia
(35/100,000 population). SAB is common, and a substan-
tial proportion of cases may be preventable. The epidemi-
ology is evolving, with >10% of community-onset SAB now
caused by MRSA. This is an emerging infectious disease
concern and is likely to impact on empiric antimicrobial drug
prescribing in suspected cases of SAB. 
Bacteremia caused by Staphylococcus aureus continuesto be a common problem worldwide. In the preantibi-
otic era, most cases occurred in young patients without
underlying disease. The associated death rate was 82% (1).
Even with antimicrobial drug treatment, death rates remain
high; in a recent meta-analysis of 31 studies, estimates of
death rates for methicillin-resistant strains (MRSA) varied
from 0.0% to 83.3% (median 34.2%), while those for
methicillin-sensitive strains (MSSA) varied from 3.6% to
51.7% (median 25.0%) (2). Many of these infections are
healthcare associated and thus are potentially preventable.
Antimicrobial drug resistance in S. aureus arose early
after the development of antimicrobial agents and contin-
ues to evolve. In Australia, hospital strains are frequently
methicillin resistant and resistant to several other antimi-
crobial drugs (3). This resistance limits the choice of
potentially efficacious agents and results in frequent use of
glycopeptides, such as vancomycin. The reliance on van-
comycin causes difficulties because vancomycin has been
shown to be less effective than isoxazolyl penicillins (e.g.,
flucloxacillin) in treating severe infections caused by S.
aureus (4,5). This may be 1 explanation for the higher
death rate associated with bacteremia caused by MRSA,
compared with that caused by MSSA (2,6). Although
MRSA tends to be the bacterium discussed most often in
relation to healthcare-associated infections, MSSA strains
are responsible for the largest proportion of hospital-
acquired infections (3).
S. aureus remains a common cause of bloodstream
infections of community onset. Increasing numbers of
these community-onset infections are being caused by
MRSA. Some of these infections may be caused by hospi-
tal strains carried into the community by patients or health-
care workers, but others are caused by true community
strains in patients who have had no recent healthcare con-
tact (7–9). These strains have emerged in many countries,
including Australia, New Zealand, the United States,
Canada, France, Switzerland, Greece, Denmark, Finland,
Scotland, and the Netherlands. They are susceptible to
most or all non–β-lactam antimicrobial drugs, are highly
pyogenic, and are often associated with indigenous popu-
lations (10,11). 
Although S. aureus is a well-known major cause of bac-
teremia, population-based estimates of its incidence are
lacking. This study used hospital data to estimate the inci-
dence of S. aureus bacteremia in Australia. In addition, we
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classified episodes on the basis of community or hospital
onset and on the basis of methicillin susceptibility.
Methods
S. aureus bacteremia data were obtained from microbi-
ology departments that prospectively collected informa-
tion for >12 months on episodes of laboratory-confirmed
bacteremia for the hospitals they serviced from January 1,
1999, to December 31, 2002. Information retrieved from
existing databases included the total number of episodes of
community- and hospital-onset bacteremia, the number of
episodes of community- and hospital-onset MRSA and
MSSA bacteremia, the total number of hospital separations
(defined as completed hospital admissions), and the mean
length of stay. Multiple positive blood cultures in the same
patient within 14 days were considered a single episode.
Episodes were considered to have a hospital onset when
the first positive blood culture was collected >48 hours
after admission to hospital. All other infections were des-
ignated community onset (for example, day-only dialysis
related episodes were defined as community onset, as were
infections with their onset in nursing homes). Organism
identification and susceptibility testing were by standard
methods. All these laboratories participate in external qual-
ity assurance programs as well as AGAR national surveys
(3,12), which have quality control procedures to ensure
these laboratories accurately detect methicillin resistance.
Published data were used for the details on the number of
hospital beds and separations for Australia and for the clas-
sification of different types of hospitals (13). The term sep-
arations, rather than admissions, is used in the published
data because hospital abstracts for inpatient care are based
on information gathered at the time of discharge. We have
used the more commonly applied term of admissions,
however, for these episodes.
In Australia, most healthcare-associated MRSA is
caused by 1 clone defined by multilocus sequence type
(ST) 239; this clone is characteristically resistant to multi-
ple antimicrobial agents, including gentamicin (3,12).
Most of the remaining healthcare-associated infections are
caused by a recently introduced strain, ST22, which is
indistinguishable from epidemic MRSA-15 in the United
Kingdom. It is invariably resistant to ciprofloxacin (12).
Thus, in Australia, MRSA that is acquired in the commu-
nity and is sensitive to both ciprofloxacin and gentamicin
is not likely to be associated with healthcare facility acqui-
sition. We used this pattern as a surrogate marker for com-
munity acquisition of MRSA without healthcare-
associated risk factors.
Results
We detected 12,771 bloodstream infections in the 17
hospitals participating in this study (12 principal referral
metropolitan, 3 large metropolitan, 1 private hospital, and
1 medium-sized public hospital, and 1 private hospital
with 2,013,534 total separations; Table 1). There were
3,192 episodes of S. aureus bacteremia identified (i.e.,
25% of the total true bloodstream infections). The median
rate of S. aureus bacteremia was higher in the principal
referral metropolitan hospitals (1.59/1000 admissions)
than in large metropolitan hospitals (1.3) or the private
hospital (0.6). The range varied from 0.60 to 3.24 (Table
2). The median rate of community-onset bacteremia
episodes was 0.80/1000 admissions (range 0.11–0.99). The
median rate of hospital-onset bacteremia was 0.72
episodes/1,000 admissions (range 0.13–1.30). The median
rate of hospital-onset MRSA episodes was 0.22/1,000
admissions (range 0–0.89). When expressed as MRSA
episodes per 1,000 occupied bed days (OBDs), the rates
varied from 0 to 0.30 with a median rate of 0.08. If day-
only cases are removed from the denominator then the
median rate was 0.10 per 1,000 OBDs (range 0–0.39). 
Of these 3,192 SAB episodes, 1,621 (51%) were of
hospital onset, and 1,571 (49%) had their onset in the com-
munity. Of those with a hospital onset, 40% were MRSA
in comparison to 12% with a community onset. Of all
MRSA bacteremia episodes, 23% had a community onset,
and 77% had hospital onset. Of the 193 community-onset
episodes of MRSA that occurred, only 47 (24%) had a sen-
sitivity pattern (sensitive to gentamicin and ciprofloxacin)
that suggests that they were community acquired. 
When both MRSA and MSSA were considered, data
were available for 560 community-onset SAB infections
(but only from 4 hospitals). The proportions of these
episodes that were noninpatient, healthcare-associated
were 35%, 42%, 18% and 16%, respectively (from hospi-
tals A, D, E, and N). In those hospitals, the percentage of
S. aureus episodes that were healthcare associated overall
(i.e., all hospital-onset cases and those community-onset
cases associated with healthcare exposure) were 75%,
69%, 64%, and 36%, respectively. 
Mortality data were available for 526 patients from 2
hospitals. At hospital E, the mortality rate at day 7 was
10% (27 of 267 patients). When a subgroup of these
patients at hospital E (52 patients) was followed for a
longer period (2001–2002), the mortality rate was 23% at
30 days and 35% at 6 months. For those 24 patients with
a community-onset episode of bacteremia that was not
healthcare associated, mortality rates were 6% at day 7,
17% at 1 month, and 21% at 6 months, respectively. At
hospital H (259 patients), the mortality rate at 30 days was
19%. At hospital H, the mean length of stay for those with
SAB was 25.6 days compared to 6.2 days in matched con-
trols. The mean length of stay was longer for MRSA
infections (39.2 days) than for MSSA infections (23.3
days).
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The rates of S. aureus bacteremia in different hospital
populations were used to estimate the incidence for
Australia. Using our median bacteremia rate for S. aureus
bacteremia in different types of public hospitals
(1.27/1,000 admissions, range 0.68–3.24) and in private
hospitals (0.6/1,000 admissions), we estimated ≈6,900
episodes per year nationally (range 3,826–20,658) or
35/100,000 per year (Tables 3 and 4). Some data are avail-
able from other countries for comparison; the lowest annu-
al rates are in Northern Ireland (23/100,000) and the
highest in the United States (56/100,000; Table 4).
However only 2 countries, Denmark and England,
appeared to have comprehensive collection systems, and
their rates were 29/100,000 and 37/100,000, respectively
(17,20,22).
Discussion
S. aureus bacteremia is very common. Approximately
one fourth (26%) of all S. aureus bacteremia episodes were
caused by MRSA, and, as expected, the onset of most of
RESEARCH
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these episodes was in hospitals (77%). Notably, however,
12% of all community-onset S. aureus infections were
MRSA, which was 23% of all MRSA bloodstream infec-
tion episodes. A recent study from the United States simi-
larly showed that 15% of community-onset SAB episodes
were MRSA (14).  Most of the community-onset strains in
our study were multiresistant or phenotypically consistent
with UK EMRSA-15 (15) and thus most likely to have
been acquired by patients who had previous hospital con-
tact, with nursing home contact a major factor in at least 1
of the hospitals in this study (hospital G). However,
approximately one fourth of these community-onset
MRSA infections were caused by other phenotypes of
non–multiresistant MRSA and thus more likely to be true
community-acquired episodes of MRSA bacteremia.
Severe cases of MRSA bacteremia not associated with
prior healthcare contact have been reported previously in
Australia (7,9,16). 
Use of the >48 hours postadmission definition of hos-
pital onset underestimates the number of episodes of bac-
teremia that are healthcare associated. Many patients with
chronic conditions are now treated in the community or
on a day-only basis. Vascular lines are increasingly used
in the community and outpatient settings, providing a
potential source of bacteremia. The collection of data on
the true association of episodes of bacteremia to health
care is time-consuming and was not done by most institu-
tions participating in this study. However, 3 principal
referral hospitals (hospitals A, D, and E) did collect these
data for 971 episodes, and 64%–75% of their total S.
aureus bacteremia episodes were healthcare associated.
Only 46%–61% of the episodes were acquired while the
patient was an inpatient (i.e., >48 h in hospital). This find-
ing means that in these larger hospitals approximately one
third of healthcare-associated episodes were acquired by
either outpatients or short-stay patients. These episodes
are better defined as “noninpatient, healthcare-associat-
ed.” In a recent study in the United States, 62% of their
community-onset SAB infections were healthcare related
(with intravenous [IV] catheters the most common clini-
cally apparent site of infection) (14). On the basis of our
data, we conclude that in Australia approximately two
thirds of all SAB episodes were associated with health-
care or medical procedures (i.e., all hospital-onset and
approximately one third of community-onset episodes). A
similar situation is evident in Denmark (17), where in
2002, at least 59% of all S. aureus infections were associ-
ated with healthcare procedures. Clearly, substantial
scope exists internationally for interventions in healthcare
settings to decrease the numbers of these episodes (espe-
cially those related to IV catheters). Interventions to
reduce S. aureus bacteremia need to target healthcare-
associated infections in the broadest sense and include
those following non–inpatient-related medical proce-
dures.
Community-onset infections that have no healthcare
association are also common and associated with a high
death rate (17% and 19% at hospitals E and H at 1 month,
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respectively). How best to intervene to decrease these
infections is difficult to determine. Vaccination is a possi-
bility for the future; a recent trial of a conjugated capsular
polysaccharide vaccine in renal dialysis patients estimated
efficacy at ≈60% (18). However, vaccination for the gen-
eral population is unlikely to be available soon. We should
therefore concentrate on reducing the number of deaths
from established infections. Because the mortality rate
associated with community-acquired bacteremia increases
with inadequate empiric therapy (19), all efforts should be
made to promote compliance with published guidelines for
treatment of severe staphylococcal sepsis, including ade-
quate duration of therapy. 
Available data suggest that staphylococcal bacteremia is
a major global health problem. The median death rate for
MSSA infections is 25%, and for MRSA infections, 34%
(20). Thus, >1,700 deaths in Australia are likely associated
with S. aureus bacteremia per year (assuming 6,900
episodes or a bacteremia rate of 35/100,000/year). This esti-
mate of the rate of SAB is similar to England (20,22) but
much lower than in the United States on the basis of the rate
derived from the figures available in the only comparative
study (55/100,000) (14). Our estimated rate in Australia is
higher than that in Denmark (17,21). It is also higher that
those reported from Wales (22) and Ireland (23) (Table 4);
however, all episodes from these last 2 countries likely were
not reported in their voluntary reporting schemes. England
changed recently from a similar voluntary reporting scheme
to a compulsory scheme, and the numbers of reported
episodes increased by almost 50% (24).
The rate of MRSA bacteremia in England was higher
per 1,000 OBDs than in our figures from Australia (0.17
compared to 0.10 episodes per 1,000 OBDs, respectively).
MRSA was a substantial cause of episodes of SAB in this
study (26%). However, this percentage was lower than that
seen in most other countries (e.g., Wales, 47%; Table 4)
with the notable exception of Denmark (0.6% in 2002)
(17).
We may have overestimated the number of cases of
bacteremia occurring in Australia because of the overrep-
resentation of larger hospitals in our survey. However,
these hospitals participated because they had in place sur-
veillance systems for measuring all episodes of bac-
teremia. The rates of SAB may have been relatively lower
in these hospitals because they were also more likely than
were hospitals without surveillance systems to have infec-
tion control programs in place to try to decrease the num-
bers of these episodes. If systems were in place that better
captured and reported on all bacteremia episodes in well-
defined populations (e.g., all of Australia or a state), then
this would give a more accurate rate. Such systems appear
only to be in place in Denmark and England (17,21,24).
Currently, no such systems are operating in Australia.
Limited data are available from a voluntary surveillance
RESEARCH
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system in Victoria (25) that captures an estimated two
thirds of bacteremic episodes that occur in that state. The
extrapolated rate (27 episodes/100,000 persons/year; Table
4) was slightly lower than what we estimated for all of
Australia in this study. 
Substantial illness and increased medical costs are also
associated with staphylococcal bacteremia. S. aureus
bacteremia is often related to serious infections, including
endocarditis, osteomyelitis, and septic arthritis. It frequent-
ly results in prolonged hospital admission and increased
costs. In hospital H, the average length of stay for patients
with S. aureus bacteremia was 26.5 days. In South
Australia, the estimated additional cost of each episode of
hospital-acquired S. aureus infection was $22,000 in 1998
(26). Nationally, these South Australian costs translate to
additional hospital costs of ≈$150 million dollars ($22,000
x 6,900 episodes).  
Treatment of S. aureus infections is complicated by the
high prevalence of antimicrobial drug resistance. Although
this has long been the case with multiresistant strains of
MRSA in hospitals, the spread of hospital strains into the
community, as well as the emergence of unique strains of
MRSA unrelated to health care, have made this an issue of
general importance. At least 3 community strains of
MRSA are currently circulating in Australia (10,27,28).
Two of these 3 community strains carry the gene for
Panton-Valentine leukocidin, which is associated with sub-
cutaneous abscess formation and necrotizing pneumonia.
A number of reports have already highlighted the clinical
impact of infection due to these strains (9,28–30).
Surveillance data show that their prevalence is increasing
in our capital cities, but the situation in rural Australia is
not well documented (3). This increase will inevitably
affect guidelines for empirical antimicrobial drug prescrib-
ing for staphylococcal infections and for patients in the
community with suspected SAB. Further surveillance of
staphylococcal infections, including bacteremia, is war-
ranted to guide recommendations for empirical therapy
and infection control interventions.
Acknowledgments
We greatly appreciate the assistance of the many laboratory
staff members at each of the participating hospitals and as well as
many infection control practitioners who assisted in the collec-
tion of the data. 
The Australian Group for Antimicrobial Resistance is cur-
rently funded by a grant from the Department of Health and
Aging of the Australian Government with funding in the past
from Eli Lilly (no funds received for 3 years).
The Australian Group on Antimicrobial Resistance
(AGAR) is a group that represents 21 teaching hospital microbi-
ology laboratories and 5 private laboratories. AGAR meets
every 6 months. At these meetings, Drs. Gottlieb and Collignon
made the initial proposal for this project. All members of AGAR
were able to participate in the discussion of the project and
Staphylococcus aureus Bacteremia, Australia
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 4, April 2005 559
suggest modifications of the project design. Only 10 hospital
laboratories had collected details on all their S. aureus bac-
teremia data prospectively, and these formed the AGAR partici-
pants able to participate in this study. Archie Darbar and Denise
Daley were involved in the collection of data at their hospitals.
Jan Roberts was involved in the collection of data at her hospi-
tal and also in the spreadsheet analysis of the data of all the
participating hospitals. 
Drs. Collignon, Nimmo, Gottlieb, and Gosbell were
involved in the writing of the manuscript. They made substantial
contributions to the conception and design of the study, as well as
to the acquisition, analysis, and interpretation of data. They also
drafted the article and revised it critically for intellectual content.
Additionally, all of the other participants in this AGAR project
provided comment and feedback on numerous drafts over a 6-
month period. All authors have reviewed this version and given
final approval for publication. 
Dr. Collignon is an infectious diseases physician as well as
a pathologist in clinical microbiology. He is a professor at the
Canberra Clinical School of the Australian National University.
His major research interests include antimicrobial resistance
from medical use and in food animals and hospital-acquired
infections, particularly bloodstream infections resulting from use
of intravascular catheters. 
References
1. Waldvogel FA. Staphylococcus aureus (including staphylococcal
toxic shock). In: Mandell GL, Bennett JE, Dolin R, editors. Principles
and practice of infectious diseases. Philadelphia: Churchill
Livingstone; 2000. p. 2069–100.
2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer
AW, Carmeli Y. Comparison of mortality associated with methicillin-
resistant and methicillin-susceptible Staphylococcus aureus bac-
teremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9.
3. Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge
JD. Antimicrobial resistance in Staphylococcus aureus in Australian
teaching hospitals 1989–1999. Microb Drug Resist. 2003;9:155–60.
4. Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R.
Staphylococcus aureus bacteremia: compliance with standard treat-
ment, long-term outcome and predictors of relapse. Scand J Infect
Dis. 2003;35:782–9.
5. Chang FY, Peacock JEJ, Musher DM, Triplett P, MacDonald BB,
Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and
the impact of antibiotic treatment in a prospective multicenter study.
Medicine (Baltimore). 2003;82:333–9.
6. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-
resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J
Aust. 2001;175:264–7.
7. Collignon P, Gosbell I, Vickery A, Nimmo G, Stylianopoulos T,
Gottlieb T. Community-acquired methicillin-resistant Staphylococcus
aureus in Australia. Lancet. 1998;352:146–7.
8. Cookson BD. Methicillin-resistant Staphylococcus aureus in the
community: new battlefronts, or are the battles lost? Infect Control
Hosp Epidemiol. 2000;21:398–403.
9. Nimmo GR, Playford EG. Community-acquired MRSA bacteraemia:
four additional cases including one associated with severe pneumo-
nia. Med J Aust. 2003;178:245.
10. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan
H, et al. Community-acquired methicillin resistant Staphylococcus
aureus carrying Panton-Valentine leukocidin genes: worldwide emer-
gence. Emerg Infect Dis. 2003;9:978–84.
11. Faria N, Oliveira DC, Westh H, Monnet DL, Larsen AR, Skov R, et
al. A new community-acquired methicillin-resistant Staphylococcus
aureus clone circulating in Denmark. In: 43rd Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chicago,
Illinois, Sept 14–17, 2003. Washington: American Society for
Microbiology; 2003. p.150.
12. Coombs GW, Nimmo GR, Bell JM, Huygens F, O’Brien FG,
Malkowski MJ, et al. Genetic diversity among community methi-
cillin-resistant Staphylococcus aureus strains causing outpatient
infections in Australia. J Clin Microbiol. 2004;42:4735–43.
13. Australian Hospital Statistics 2001–02. In: Health services series.
Canberra: Australian Institute of Health and Welfare; 2003 [cited July
26, 2004]. Available from http://www.aihw.gov.au/publications/
hse/ahs01-02/index.html
14. Morin CA, Hadler JL. Population-based incidence and characteristics
of community-onset Staphylococcus aureus infections with bac-
teremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis.
2001;184:1029–34.
15. Johnson AP, Aucken HM, Cavendish S, Ganner M, Wale MC, Warner
M, et al. Dominance of EMRSA-15 and -16 among MRSA causing
nosocomial bacteraemia in the UK: analysis of isolates from the
European Antimicrobial Resistance Surveillance System (EARSS). J
Antimicrob Chemother. 2001;48:143–4.
16. Collins N, Gosbell lB, Wilson SF. Community-acquired MRSA bac-
teraemia. Med J Aust. 2002;177:55–6.
17. Danish Staphylococcus aureus bacteremia group. Annual report on
Staphylococcus aureus bacteremia in Denmark, 2002. Statens Serum
Institut. Published 8/06/2004 [cited July 26, 2004]. Copenhagen.
Available from http://www.ssi.dk/graphics/dk/overvagning/Annual02.
pdf
18. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et
al. Use of a Staphylococcus aureus conjugate vaccine in patients
receiving hemodialysis. N Engl J Med. 2002;346:491–6.
19. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-
acquired bloodstream infection in critically ill adult patients: impact
of shock and inappropriate antibiotic therapy on survival. Chest.
2003;123:1615–24.
20. The second year of the Department of Health’s mandatory MRSA bac-
teraemia surveillance scheme in acute Trusts in England: April
2002–March 2003 [cited July 26, 2004]. CDR Weekly. 2003;13:1–9.
Available from http://www.hpa.org.uk/cdr/PDFfiles/2003/cdr2503.pdf
21. Schonheyder HC. Two thousand seven hundred and thirty nine
episodes of bacteremia in the county of Northern Jutland 1996–1998.
Presentation of a regional clinical database. Ugeskr Laeger.
2000;162:2886–91.
22. Staphylococcus aureus bacteraemia: England, Wales and Northern
Ireland, January to December 2003. CDR Wkly. 2004;14:1–5. [cited
February 28, 2005]. Available from http://www.hpa.org.uk/cdr/
PDFfiles/2004/staph_ann_1604.pdf
23. McDonald P, Mitchell E, Johnson H, Rossney A. Epidemiology of
MRSA: the North/South study of MRSA in Ireland 1999. J Hosp
Infect. 2003;54:130–4.
24. Staphylococcus aureus bacteraemia: England, Wales and Northern
Ireland, January to December 2002. CDR Wkly. 2003;13: March 20
[cited February 28, 2005]. Available from http://www.hpa.org.uk/
cdr/PDFfiles/2004/staph_ann_1604.pdf
25. Veitch M. Staphylococcus aureus bacteraemia in Victoria, 1990–1999.
In: Communicable Diseases Network of Australia Conference.
Canberra, Australia: 2001. p. 18, no. 23 [cited July 26,2004]. Available
from http://www.cda.gov.au/cdna/pdf/cdc01abs.pdf.
RESEARCH
560 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 4, April 2005
26. An Expert Working Group of the Australian Infection Control
Association. National surveillance of healthcare associated infection
in Australia. 2001 [cited July 26, 2004]. Available from
http://www.health.gov.au/pubhlth/strateg/jetacar/pdf/scope.pdf
27. Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, O’Brien
FG, et al. Dissemination of new methicillin-resistant Staphylococcus
aureus clones in the community. J Clin Microbiol. 2002;40:4289–94.
28. Munckhof WJ, Schooneveldt J, Coombs GW, Hoare J, Nimmo GR.
Emergence of community-acquired methicillin-resistant Staphylo-
coccus aureus (MRSA) infection in Queensland, Australia. Int J
Infect Dis. 2003;7:259–67.
29. Gosbell IB, Mercer JL, Neville SA, Crone SA, Chant KG, Jalaludin
BB, et al. Non-multiresistant and multiresistant methicillin-resistant
Staphylococcus aureus in community-acquired infections. Med J
Aust. 2001;174:627–30.
30. Nimmo GR, Schooneveldt J, O’Kane G, McCall B, Vickery A.
Community acquisition of gentamicin-sensitive MRSA in south-east
Queensland. J Clin Microbiol. 2000;38:3926–31.
Address for correspondence: Peter Collignon, Infectious Diseases Unit
and Microbiology Department, The Canberra Hospital, PO Box 11,
Woden, Australian Capital Territory 2602, Australia; fax: 61-2-6281-
0349; email: peter.collignon@act.gov.au
Staphylococcus aureus Bacteremia, Australia
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 4, April 2005 561
